MVA-BN filovirus vaccine - Bavarian Nordic

Drug Profile

MVA-BN filovirus vaccine - Bavarian Nordic

Alternative Names: Ebola Marburg virus vaccine - Bavarian Nordic; Marburg Ebola virus vaccine - Bavarian Nordic; Modified Vaccinia Ankara Bavarian Nordic Marburg Ebola vaccine; MVA-BN Filo; MVA-BN-EBOV-MARV; MVA-BN-MARV-EBOV

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bavarian Nordic
  • Developer Bavarian Nordic; Crucell; University of Maryland, Baltimore; Wellcome Trust
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ebola virus infections
  • Phase II Marburg virus disease

Most Recent Events

  • 28 Nov 2017 No recent reports of development identified for phase-I development in Ebola-virus-infections(Prevention) in Mali (IM, Injection)
  • 02 May 2017 The University of Oxford initiates enrolment in the phase I extension PRISM trial for Ebola virus infections (Prevention, Combination therapy) in United Kingdom (NCT03140774)
  • 18 Apr 2017 Bavarian Nordic in-licenses EB66® cell-line technology from Valneva
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top